Trish and John O'Donnell Provide Foundational Support for a Comprehensive Melanoma Program at Hoag Family Cancer Institute
Melanoma rates in Orange County are among the highest in the world. Thanks to the generous support of Trish and John O’Donnell, Hoag is fulfilling its commitment to develop a comprehensive melanoma program. Under the leadership of Hoag Family Cancer Institute Executive Medical Director, Burton Eisenberg, M.D., Grace E. Hoag Endowed Chair and Professor of Clinical Surgery, Keck School of Medicine of USC, the program in alliance with Keck Medicine of USC, will address the full spectrum of care, from prevention and early detection to leading-edge treatment options that address advanced and recurrent disease. “We are quite grateful to the O’Donnells for their understanding of the community need for a comprehensive program,” says Dr. Eisenberg. “Their gift provides the foundational support for program development and enhancement. Their generous action on behalf of our community will helps us create a sustainable program that will save lives.”
The O’Donnells, whose son had a brush with melanoma at age 27, are thrilled to support this important program and the renowned physician behind it. “Living in Southern California, we are all exposed to the sun year-round,” shares Trish. “John and I believe that it’s important to have a robust program where it’s needed the most.”
John adds, “We are pleased that our community has a physician leader of the caliber of Dr. Eisenberg at the helm of the Hoag Family Cancer Institute. He’s focusing his career on saving lives right here in our backyard, and Trish and I are honored to support him in his important work.”
According to Dr. Eisenberg, the O’Donnell’s gift will assist him in recruiting physician expertise to treat melanoma from early action and surveillance to interventional therapies. The impact will spread as the melanoma program physicians become resources for community dermatology and family practice physicians. It will also allow him to integrate clinical trials and incorporate advanced genetic and genomic testing.
*In memory of John O'Donnell